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Malignant mesothelioma is an aggressive tumour arising from
serous surfaces. It is usually related to asbestos exposure and
generally resistant to conventional chemotherapy.
Only a few single chemotherapeutic agents have been reported
to produce response rates greater than 20% in patients with pleural
mesothelioma. Among the most promising agents have been
anthracyclines (detorubicin and pirarubicin), ifosfamide, mito-
mycin and some antifolates such as methotrexate (MTX) in high
doses and edatrexate (Ong and Vogelzang, 1996; Ryan et al, 1998).
High-dose MTX was first reported to induce objective
responses in patients with mesothelioma by Dimitrov et al (1982)
who treated nine patients with MTX at 1500 mg m–2 as a contin-
uous infusion with citrovorum rescue and vincristine. In this early
study tumour response was assessed without computerized tomog-
raphy using chest radiographs and sonograms. Three complete
responses (CR) and three partial responses (PR) were achieved,
while three patients showed no change (NC), but had less need of
fluid removal. Two of the responders (PR) had not received any
prior therapy, while the others had received two chemotherapeutic
agents or one chemotherapy agent plus radiotherapy and surgical
debulking before starting high-dose MTX. Duration of response
and survival of the responders were 2–23 months and 5–35 months
respectively (Dimitrov et al, 1982). Solheim et al (1992) reported
on 63 patients with pleural mesothelioma who were treated with
4–8 courses of MTX at 3 g with citrovorum rescue. Of 60 patients
evaluable for response (assessed using computerized tomog-
raphy), 37% achieved PR (n = 21) or CR (n = 1). Median survival
for all patients was 11 months and 40% of the patients were alive
after 1 year. Toxicity was acceptable, with one toxic death and five
patients (8%) discontinuing treatment due to toxicity (Solheim et
al, 1992).
In experimental studies both natural and recombinant interferon
(IFN)-a have been reported to have inhibitory effects on human
mesothelioma xenograft lines (Sklarin et al, 1988; Ohnuma et al,
1993). In a clinical study of 13 patients with pleural mesothelioma
one response was achieved using systemic administration of
recombinant IFN-a2b (Ardizzoni et al, 1994), and in another study
of 25 mesothelioma patients recombinant IFN-a2a induced one
CR and two PRs (response rate 12%) (Christmas et al, 1993).
However, no responses were noted when 14 mesothelioma
patients were administered recombinant IFN-b systemically (Von
Hoff et al, 1990), although eight CRs and nine PRs (objective
response rate 20%) were achieved using intrapleurally instilled
recombinant IFN-g to treat 89 patients with mesothelioma. Most of
these responders had early stage disease (Boutin et al, 1994). After
the Boutin report, Zeng et al (1993) demonstrated a large range of
responses to recombinant human IFN-g in experimental studies on
32 human mesothelioma cell lines.
The antiproliferative effects of IFN-a and IFN-g both alone and
in combination with various chemotherapeutic agents on mesothe-
lioma cell lines has been demonstrated in the earlier studies of our
group (Hand et al, 1991). After the Solheim report on high-dose
MTX therapy for patients with pleural mesothelioma, we tested
the combination of IFN-a and IFN-g with MTX in four human
mesothelioma cell lines. IFN-a and IFN-g in combination
augmented the response of the cell lines to MTX better than either
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Summary Twenty six patients with pleural mesothelioma of UICC stage I–IV excluding M1 disease (46% of whom had stage I disease and
38% stage III disease) were treated intravenously with high dose MTX (3 g) and calcium folinate rescue three times at intervals of 2 weeks
and three times at intervals of 3 weeks. Natural interferon (IFN)-a (3 MIU days 2–10) and recombinant IFN-g 1b (50 mg m–2 on days 2, 6 and
10) were injected subcutaneously after each MTX dose. At the end of MTX treatment the IFNs were continued as maintenance therapy until
disease progression. Seven partial responses were observed among 24 patients evaluable for response (response rate 29%, 95%
confidence interval 13–51%). Median duration of response was 10 months (range 3–24 months). Median survival was 17 months and 1-year
and 2-year survival rates 62% and 31% respectively. The toxicity of the chemo-immunotherapy was acceptable. Treatment was stopped in
one patient who developed grade IV neurological toxicity. MTX dose reductions were rare (two patients with grade 1–2 renal toxicity). The
combination of high dose MTX and IFN-a and IFN-g is active against malignant pleural mesothelioma and well-tolerated. The survival rates
are encouraging.
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and it was found to have a similar sensitivity profile to that of
IFN-a (Hand et al, 1995).
The aim of this clinical phase II study was to investigate the
activity and to evaluate the toxicity of the combination of high-
dose MTX with IFN-a and IFN-g in patients with malignant
pleural mesothelioma.
MATERIALS AND METHODS
Patient selection
Patients with previously untreated, histologically confirmed (by a
panel of pathologists) malignant pleural mesothelioma were
eligible for the study. Additional entry criteria were age 18–70
years, performance status WHO 0–1, tumour classification
T1–3N0–3M0 as verified by computerized tomography (CT)
within 14 days, measurable tumour lesion (assessed using CT),
adequate bone marrow reserve (WBC > 3 ´ 109 l–1 and platelet
count > 100 ´ 109 l–1, adequate liver and renal function (serum
creatinine and transaminase levels < twice the upper normal limit).
Patients with other malignant disease (except stage I cervix carci-
noma), severe cardiac disease, severe mental disturbance or a
known seizure disorder were excluded. All patients gave informed
written consent before starting the treatment. The study was
approved by the Ethics Committee of the Division of Pulmonary
Medicine and Clinical Physiology, Department of Medicine at the
Helsinki University Central Hospital.
Treatment schedule
Patients were assigned to receive six doses of MTX with calcium
folinate rescue in combination with subcutaneous injections of
IFN-a and IFN-g. Chest radiographs and laboratory tests including
total blood cell count, transaminases, alkaline phosphatase, serum
bilirubin, potassium, sodium, C-reactive protein and urine analysis
were checked before each MTX infusion and at the end of the
treatment. Response was evaluated from CT scans of the chest and
upper abdomen after three doses and six doses of MTX and at any
suspicion of tumour progression. The treatment was discontinued
if progressive disease (PD) was detected. For patients who
achieved objective responses the treatment could be continued
beyond six doses. Toxicity was evaluated using WHO criteria. All
patients were re-evaluated 1, 3 and 6 months after discontinuing
treatment and thereafter when progression was suspected using
above-mentioned laboratory tests and CT. Survival was calculated
from the first MTX dose.
Methotrexate
Urine had to be kept alkaline (pH > 8.0) to secure adequate excre-
tion of soluble MTX. The day before MTX treatment patients
received 200 ml bicarbonate solution (500 mmol l–1) as well as
started taking bicarbonate tablets (3 g) four times a day for 5 days.
The pH of urine was measured four times per 24 h and the bicar-
bonate dose was increased if the urinal pH dropped below 8.0.
Methotrexate (TrexanR) 3 g was administered on days 0, 14, 28,
49, 70 and 91. Sufficient hydration was maintained with a total
fluid intake of at least 2500 ml every 24 h until the MTX concen-
tration fell below 0.1 mmol l–1. Calcium folinate (AntrexR) rescue
was initiated 24 h after the start of MTX treatment using 15 mg
(either orally or intravenously) every 6 h for a minimum of
11 doses. Further treatment was administered if the MTX concen-
tration in serum had not dropped below 0.1 mmol l–1 96 h after the
MTX infusion. Calcium folinate treatment was then continued
until the MTX level was below 0.08 mmol l–1.
Interferons
Interferon treatment was only started after the MTX concentration
in serum had decreased to 0.2 mM. Natural IFN-a (WellferonR)
3 MIU was administered subcutaneously on days 2–10 after each
dose of MTX. It was continued at the same dose three times
a week after the MTX treatment had finished until disease
progression.
Recombinant IFN-g 1b (ImukinR) 50 mg m–2 (maximum 100 mg)
was administered subcutaneously on days 2, 6 and 10 after
each dose of MTX. When the MTX treatment was completed
IFN-g was continued at the initial dose once a week until disease
progression.
Response criteria
Tumour response was assessed from CT scans of the chest and
upper abdomen according to the World Health Organization
(WHO) criteria. All scans were reviewed by a radiologist.
Response was assessed according to the following criteria. CR
was defined as the disappearance of all tumour tissue and pleural
exudate. PR required the disappearance of at least 50% of tumour
tissue within all marker lesions. Progressive disease required an
increase of at least 25% in tumour size. NC indicated stable
disease with less change in the tumour size than PR or PD.
Statistical analysis
Differences in patient characteristics between responders and non-
responders were analysed using Fisher’s exact test. Confidence
intervals for the response rates were computed using a binomial
distribution. Survival was estimated using the life-table method.
RESULTS
Twenty six patients met the entry criteria between March 1992 and
May 1997. Clinical characteristics of the patients are given in
Table 1. According to the staging system proposed by UICC
(Union Internationale Contre le Cancer) (UICC 1992) 46%
(12/26) of the patients had stage I disease. Another 46% (12/26) of
the patients had more advanced stage III–IV disease due to several
T3 tumours and two patients with grade 3 nodal status. Subtype
analysis revealed epithelial histology in 65% (17/26) of the
patients. One patient had a sarcomatoid tumour and the rest had
mixed type tumours. Twenty-one patients (81%) were known to
have been exposed occupationally to asbestos.
Between one and six doses of MTX (mean 5.1) were given to
each patient. Eighteen patients received all six cycles of scheduled
treatment. Two of these patients received additional six doses of
MTX because of continuing response. Two patients received only
one dose of MTX. Both patients had rapidly progressive disease
and at the time of the second dose the other one had respiratory
infection as well. Their treatment was decided to be discontinued
before the second dose due to poor performance status. These
patients were determined non-evaluable for response analysis.
Reduced doses (1.5–2 g) were given to two patients.
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tumour progression within 1–22 months (mean 5.9) of discontin-
uing MTX. All these patients received radiotherapy (palliative
doses of 20–30 Gy for 14 patients and 50 Gy for nine patients).
Seven patients received other chemotherapy (docetaxel five
patients, camptothecin one patient, paclitaxel + carboplatin one
patient). Two of the patients who were not given any additional
therapy died early of progressive disease.
Response to treatment
Twenty four (92.3%) patients were evaluable for tumour response.
None of the patients achieved CR but there were seven PRs (objec-
tive response rate 29%, [95% confidence interval (CI) 13–51%]).
Four patients in the responder group had epithelial tumours while
the others had tumours of mixed histology. There were 13 epithe-
lial, three mixed and one sarcomatoid tumour in the non-responder
group. Five of the responders had stage I disease and two had stage
III disease. In the non-responder group seven patients had stage I
disease, one patient stage II disease, eight patients stage III disease
and one patient stage IV disease. Three of the responders had a
performance status of WHO grade 0 and four of grade 1, as
opposed to seven and 10, respectively, in the non-responder group.
All except one of the patients evaluable for tumour response
received radiotherapy after MTX treatment. Other chemotherapy
was given to three responders and four non-responders. There
were no statistical differences in tumour histology, tumour stage,
performance status or additional therapies between responders and
non-responders. The maximum response was observed after three
cycles in five patients, although two patients only responded after
six cycles. Median duration of response was 10 months ranging
from 3 to 24 months. Fourteen patients showed NC, and three
patients PD after three cycles. Nine of the NC patients retained the
same status after six cycles. Median time to progression for all
patients was 4 months (range 2 weeks to 24 months).
Survival
All 26 patients meeting the entry criteria were included in the
survival analysis. Median survival of all patients was 17 months
(range 3.5–36+ months) and 1- and 2-year survival rates were 62%
and 31% respectively (Figure 1). One-year survival rates for the
responders (n = 7) and non-responders (n = 17) were 85.7% and
64.7% respectively (not significant), and two-year survival rates
57.1% and 11.8% respectively (P < 0.05). Five patients (two in the
responder group) were alive at the time of evaluation.
Toxicity
All patients were evaluable for toxicity (Table 2). Leukopenia was
the most common haematological toxicity occurring in all patients.
Seven patients (27%) had WHO grade 3 leukopenia, while the
remaining 19 had grade 1–2. WHO grade 1–2 anaemia occurred
in five patients (19%). WHO grade 1 thrombocytopenia was only
detected in one patient.
Fourteen patients suffered from non-haematological toxicity
during the chemo-immunotherapy. WHO grade 3 gastrointestinal
toxicity (elevation in transaminase levels) occurred in three (12%)
patients while grade 1–2 toxicity occurred in nine patients. Two
patients had renal toxicity (elevation in creatinine levels) of WHO
grade 2 and one patient of grade 1. Renal toxicity lead to reduc-
tions in the MTX dose for two patients (1.5 g and 2 g).
Two patients suffered from WHO grade 2 rash. One patient
developed hemiparesis 10 days after the third MTX dose. This
adverse event was graded as WHO grade 4 neurological toxicity
and led to the discontinuation of treatment despite a PR. A CT of
the brain, electroencephalography and a thorough neurological
evaluation did not provide any explanation of this event which was
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Table 1 Patient characteristics
N 26
Sex
Males 23
Females 3
Age (years)
Mean 55
Range 43–70
Histology
Epithelial 17
Sarcomatoid 1
Mixed 8
Clinical stage
I1 2
II 2
III 10
IV 2
Performance status
(WHO Grade)
01 0
11 6
Table 2 Toxic effects during methotrexate + IFN treatment
Grade (WHO criteria)
Toxicity 1 2 3 4
Haematological
Anaemia 2 3 0 0
Leukopenia 7 12 7 0
Thrombocytopenia 1 0 0 0
Gastrointestinal 7 2 3 0
Renal 1 2 0 0
Neurological 0 0 0 1
Cutaneous 0 2 0 0
100%
0%
80%
60%
40%
20%
0123
Years
n = 26
Figure 1 Survival of all patientsreversible. Later the patient received palliative radiotherapy after
PD and died 3 months later of progressive disease. MTX-related
mucositis was not observed in any of our patients.
During IFN maintenance therapy toxicity was mild and tran-
sient. WHO grade 1 leukopenia was detected in three patients.
Elevation of transaminase levels was detected in four patients (one
grade 3, two grade 2 and one grade 1). Flu-like symptoms were
common side-effects of IFN treatment but required no dose adjust-
ments. They were usually clinically manageable, although one
patient stopped administering IFN because of this side-effect.
DISCUSSION
This study is the first clinical report on the combination of MTX
and IFN used against mesothelioma. The objective response rate
29% (95% CI 13–51%), confirms MTX as an active agent, but in
the light of Solheim’s study which achieved a response rate of
37% using the same MTX dose and time schedule, no benefit can
be attributed to the addition of IFN in our regime (Solheim et al,
1992). Our slightly lower response rate cannot be attributed to
dosage either because we gave full doses of MTX to all except two
patients (who had elevations in creatinine levels as a result of the
first dose of MTX). One reason could be that there was more
advanced disease in our patient population than in Solheim’s
population. Forty-six per cent of our patients had stage III–IV
disease compared to 10% in the Solheim study (Solheim et al,
1992). However, the response rate achieved by Solheim lies within
the 95% confidence interval of our response rate.
The survival rates in our study are more favourable than in the
Solheim study. When analysing the survival figures we must,
however, take into account the other treatments given to our
patients. Seven of our 26 patients received other chemotherapy
after finishing the MTX regime which may have affected survival.
Radiotherapy was given to 23 patients with bulky disease, mainly
for pain alleviation. Importantly, however, the additional treat-
ments given to our patients were comparable for responder and
non-responder groups and cannot explain the significantly longer
survival time in the responder group. Solheim did not record
survival for responders and non-responders, but the median
survival of all his patients was shorter than in our study (11 vs 17
months) despite of the more advanced disease in our patient popu-
lation.
MTX at conventional doses has been combined successfully
with other chemotherapeutic agents in the treatment of mesothe-
lioma. Hunt et al (1996) reported two CRs among nine responders
(response rate 53%, 95% CI 28–77%) in a study of 17 mesothe-
lioma patients treated with cisplatin and vinblastine combined
with MTX at a dose of 30 mg m–2, which exceeds the response
achieved using MTX alone. Doxorubicin is another cytotoxic
agent which has been reported to induce objective responses of at
least 30% of mesothelioma patients, when used in combination.
The combination of cisplatin, cyclophosphamide and doxorubicin
has been reported to produce a response rate of 30% (Shin et al,
1995). Two CRs and one PR were achieved using high dose
doxorubicin (90 mg m–2) combined with cisplatin for patients with
mesothelioma in a study reported by Stewart et al. Although this
was a pilot study with only four patients, the prolonged survival of
these patients (> 4 years in one patient) is a promising result
(Stewart et al, 1994). Doxorubicin at a dose of 75 mg m–2
combined with ifosfamide produced seven PRs (response rate
32%, 95% CI 13–51%) in 22 patients, although median duration of
response as well as median survival were short, 6 months and
7 months respectively (Dirix et al, 1994).
Recombinant IFN-a2a has been combined with doxorubicin in
a clinical trial for 25 mesothelioma patients. Four PRs were
achieved, giving a response rate of 16% (Upham et al, 1993).
Augmentation of the efficacy of the chemotherapeutic agent by
IFN was not therefore confirmed by this study. Tansan et al (1994)
combined recombinant IFN-a2b with cisplatin and mitomycin C
and achieved only two PRs among 19 evaluable mesothelioma
patients. They also concluded that the addition of IFN-a to cyto-
toxic agents did not result in an objective response higher than
previously reported for the agents alone (Tansan et al, 1994).
Furthermore, Pass et al (1995) reported a response rate of 19% in
36 mesothelioma patients after cisplatin, oral tamoxifen and
subcutaneously administrated IFN-a2b given four times a week.
However, weekly cisplatin combined with subcutaneously admini-
stered IFN-a2a produced ten PRs among 25 mesothelioma
patients (response rate 40%, 95% CI 20–60%), indicating that IFN
can have an additive or synergistic effect on cisplatin. Median
survival of the responders was significantly higher than in the non-
responder group (25 vs 8 months) (Soulie et al, 1996).
Response evaluation in mesothelioma is not standardized and
only recently has a staging classification been recommended that
allows inter-trial comparisons (Rusch, 1995). The relatively small
studies so far reported have therefore been difficult to compare and
no data could have been regarded as baseline for future trials. The
two MTX studies are exceptions in this context. Both Solheim’s
report on 63 patients and our report on 26 patients indicate that
MTX at a relatively high dose is active against mesothelioma. The
survival figures in our study are encouraging. The contributory
effect of IFN on survival benefit remains open; a proper assess-
ment would require a randomized trial.
REFERENCES
Ardizzoni A, Pennucci MC, Castagneto B, Mariani GL, Cinquegrana A, Magri D,
Verna A, Salvati F and Rosso R (1994) Recombinant interferon alpha-2b in the
treatment of diffuse malignant pleural mesothelioma. Am J Clin Oncol (CCT)
17: 80–82
Boutin C, Nussbaum E, Monnet I, Bignon J, Vanderschueren R, Guerin J-C, Menard
O, Mignot P, Dabouis and Douillard J-Y (1994) Intrapleural treatment with
recombinant gamma-interferon in early stage malignant pleural mesothelioma.
Cancer 74: 2460–2467
Christmas TI, Manning LS, Garlepp MJ, Musk AW and Robinson BW (1993) Effect
of interferon-alpha 2a on malignant mesothelioma. J Interferon Res 13: 9–12
Dimitrov NV, Egner J, Balcueva E and Suhrland LG (1982) High-dose methotrexate
with citrovorum factor and vincristine in the treatment of malignant
mesothelioma. Cancer 50: 1245–1247
Dirix LY, van Meerbeeck J, Schrijvers D, Corthouts B, Prove A, van Marck E,
Vermeire P and van Oosterom AT (1994) A phase II trial of dose-escalated
doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma.
Ann Oncol 5: 653–655
Hand AM, Husgafvel-Pursiainen K, Tammilehto L, Mattson K and Linnainmaa K
(1991) Malignant mesothelioma: the antiproliferative effect of cytokine
combinations on three human mesotelioma cell lines. Cancer Lett 58: 205–210
Hand AM, Pelin K, Mattson K and Linnainmaa K (1995) Interferon (IFN)-a and
IFN-g in combination with methotrexate: in vitro sensitivity studies in four
human mesothelioma cell lines. Anti-Cancer Drugs 6: 77–82
Hunt KJ, Longton G, Williams MA and Livingston RB (1996) Treatment of
malignant mesothelioma with methotrexate and vinblastine, with or without
platinum chemotherapy. Chest 109: 1239–1242
Ohnuma T, Szrajer L, Holland JF, Kurimoto M and Minowada J (1993) Effects of
natural interferon alpha, natural tumor necrosis factor alpha and their
combination on human mesothelioma xenografts in nude mice. Cancer
Immunol Immunother 36: 31–36
1784 M Halme et al
British Journal of Cancer (1999) 80(11), 1781–1785 © 1999 Cancer Research Campaign Ong S and Vogelzang NJ (1996) Chemotherapy in malignant pleural mesothelioma:
a review. J Clin Oncol 14: 1007–1017
Pass HW, Temeck BK, Kranda K, Steinberg SM and Pass HI (1995) A phase II trial
investigating primary immunochemotherapy for malignant pleural
mesothelioma and the feasibility of adjuvant immunochemotherapy after
maximal cytoreduction. Ann Surg Oncol 2: 214–220
Rusch V (1995) A proposed new international TNM staging system for malignant
pleural mesothelioma. Chest 108: 1122–1128
Ryan CW, Herndon J and Vogelzang NJ (1998) A review of chemotherapy trials for
malignant mesothelioma. Chest 113: 66S–73S
Shin DM, Fossella FV, Umsawasdi T, Murphy WK, Chasen MH, Walsh G, Komaki
R, McMurtrey MJ and Hong WK (1995) Prospective study of combination
chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for
unresectable or metastatic malignant pleural mesothelioma. Cancer 76:
2230–2236
Sklarin NT, Chaninian AP, Feuer EJ, Lahman LA, Szrajer L and Holland JF (1988)
Augmentation of activity of cis-diamminedichloroplatinum(II) and mitomycin
C by interferon in human malignant mesothelioma xenografts in nude mice.
Cancer Res 48: 64–67
Solheim OP, Säter G, Finnanger AM and Stenwig AE (1992) High-dose
methotrexate in the treatment of malignant mesothelioma of the pleura.
A phase II study. Br J Cancer 65: 956–960
Soulie P, Ruffie P, Trandafir L, Monnet I, Tardivon A, Terrier P, Cvitkovic E, Le
Chevalier T and Armand JP (1996) Combined systemic chemoimmunotherapy
in advanced diffuse malignant mesothelioma: report of phase I–II study of
weekly cisplatin/interferon a-2a. J Clin Oncol 14: 878–885
Stewart DJ, Gertler SZ, Tomiak A, Shamji F, Goel R, Evans WK (1994) High dose
doxorubicin plus cisplatin in the treatment of unresectable mesotheliomas:
report of four cases. Lung Cancer 11: 251–258
Tansan S, Emri S, Selcuk T, Koc Y, Hesketh P, Heeren T, McCaffrey RP and Baris
YI (1994) Treatment of malignant pleural mesothelioma with cisplatin,
mitomycin C and alpha interferon. Oncology 51: 348–3451
UICC (1992) International Union against Cancer: TNM Classification of Malignant
Tumours. Springer Verlag: Berlin.
Upham JW, Musk AW, van Hazel G, Byrne M and Robinson BW (1993) Interferon
alpha and doxorubicin in malignant mesothelioma: a phase II study. Aust NZ J
Med 23: 683–687
Von Hoff DD, Metch B, Lucas JG, Balcerzak SP, Grunberg SM and Rivkin SE
(1990) Phase II evaluation of recombinant interferon-beta (IFN-b ser) in
patients with diffuse mesothelioma: a Southwest Oncology Group study.
J Interferon Res 10: 531–534
Zeng L, Buard A, Monnet I, Boutin C, Fleury J, Saint-Etienne L, Brochard P, Bignon
J and Jaurand MC (1993) In vitro effects of recombinant human interferon
gamma on human mesothelioma cell lines. Int J Cancer 55: 515–520
High-dose MTX with IFNs for pleural mesothelioma 1785
British Journal of Cancer (1999) 80(11), 1781–1785 © 1999 Cancer Research Campaign 